These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 10194825)

  • 1. Rationale for a vaccine using cellular-derived epitope presented by HIV isolates.
    Galéa P; le Contel C; Coutton C; Chermann JC
    Vaccine; 1999 Mar; 17(13-14):1700-5. PubMed ID: 10194825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel epitope R7V common to all HIV-1 isolates is recognized by neutralizing IgG found in HIV-infected patients and immunized rabbits.
    Galéa P; Le Contel C; Chermann JC
    Vaccine; 1999 Mar; 17(11-12):1454-61. PubMed ID: 10195781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Investigation of anti-R7V antibodies in HIV-infected patients under highly active antiretroviral therapy].
    Ergünay K; Altinbaş A; Calik Başaran N; Unal S; Us D; Karabulut E; Ustaçelebi S
    Mikrobiyol Bul; 2008 Jul; 42(3):413-9. PubMed ID: 18822884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
    Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
    J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Membrane bound Indian clade C HIV-1 envelope antigen induces antibodies to diverse and conserved epitopes upon DNA prime/protein boost in rabbits.
    Rangasamy SP; Menon V; Dhopeshwarkar P; Pal R; Vaniambadi KS; Mahalingam S
    Vaccine; 2016 May; 34(21):2444-2452. PubMed ID: 27032514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and studies of the anti-R7V neutralizing antibody ELISA test: a new serological test for HIV seropositive patients.
    Sanchez A; Gemrot F; Da Costa Castro JM
    J Immunol Methods; 2008 Mar; 332(1-2):53-60. PubMed ID: 18234206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of high levels of antibodies recognizing the neutralizing epitope ELDKWA and the D- or K-position-mutated epitopes by candidate epitope vaccines against HIV-1.
    Xiao Y; Dong X; Chen Y
    Int Arch Allergy Immunol; 2000 Aug; 122(4):287-92. PubMed ID: 10971120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyepitope protein incorporated the HIV-1 mimotope recognized by monoclonal antibody 2G12.
    Karpenko LI; Scherbakova NS; Chikaev AN; Tumanova OY; Lebedev LR; Shalamova LA; Pyankova OG; Ryzhikov AB; Ilyichev AA
    Mol Immunol; 2012 Apr; 50(4):193-9. PubMed ID: 22341130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A recombinant human monoclonal anti-R7V antibody as a potential therapy for HIV infected patients in failure of HAART.
    Haslin C; Lévêque M; Ozil A; Cérutti P; Chardès T; Chermann JC; Duonor-Cérutti M
    Hum Antibodies; 2007; 16(3-4):73-85. PubMed ID: 18334743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 10E8-like neutralizing antibodies against HIV-1 induced using a precisely designed conformational peptide as a vaccine prime.
    Yu Y; Tong P; Li Y; Lu Z; Chen Y
    Sci China Life Sci; 2014 Jan; 57(1):117-27. PubMed ID: 24369352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.
    Hessell AJ; McBurney S; Pandey S; Sutton W; Liu L; Li L; Totrov M; Zolla-Pazner S; Haigwood NL; Gorny MK
    Vaccine; 2016 May; 34(24):2713-21. PubMed ID: 27102818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a novel multi-immunogen vaccine strategy for targeting 4E10/10E8 neutralizing epitopes on HIV-1 gp41 membrane proximal external region.
    Banerjee S; Shi H; Banasik M; Moon H; Lees W; Qin Y; Harley A; Shepherd A; Cho MW
    Virology; 2017 May; 505():113-126. PubMed ID: 28237764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
    Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
    Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes.
    Lorin C; Delebecque F; Labrousse V; Da Silva L; Lemonnier F; Brahic M; Tangy F
    Vaccine; 2005 Aug; 23(36):4463-72. PubMed ID: 15993518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope.
    Correia BE; Ban YE; Holmes MA; Xu H; Ellingson K; Kraft Z; Carrico C; Boni E; Sather DN; Zenobia C; Burke KY; Bradley-Hewitt T; Bruhn-Johannsen JF; Kalyuzhniy O; Baker D; Strong RK; Stamatatos L; Schief WR
    Structure; 2010 Sep; 18(9):1116-26. PubMed ID: 20826338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epitope-vaccines: a new strategy to induce high levels of neutralizing antibodies against HIV-1.
    Xiao Y; Liao M; Lu Y; Dierich MP; Chen YH
    Immunobiology; 2000 Jan; 201(3-4):323-31. PubMed ID: 10776789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of neutralizing epitopes on multiple-epitope vaccines against HIV-1.
    Lu Y; Xiao Y; Ding J; Dierich M; Chen YH
    Int Arch Allergy Immunol; 2000 Jan; 121(1):80-4. PubMed ID: 10686512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of the EC26-2A4 Epitope in the gp41 Membrane Proximal External Region Targeted by Neutralizing Antibodies from an Elite Controller.
    Ringel O; Müller K; Koch J; Brill B; Wolf T; Stephan C; Vieillard V; Debré P; Dietrich U
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):365-374. PubMed ID: 29262692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
    Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
    Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response.
    Cleveland SM; Buratti E; Jones TD; North P; Baralle F; McLain L; McInerney T; Durrani Z; Dimmock NJ
    Virology; 2000 Jan; 266(1):66-78. PubMed ID: 10612661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.